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Abstract
Novel approaches are needed to define subgroups of patients with Idiopathic pulmonary fibrosis (IPF) at risk for
acute exacerbations and/or accelerated progression of this generally fatal disease. Progression of disease is an
integral component of IPF with a median survival of 3 to 5 years. Conversely, a high degree of variability in disease
progression has been reported among series. The characteristics of patients at risk of earlier death predominantly
rely on baseline HRCT appearance, but this concept that has been challenged. Disparate physiological approaches
have also been taken to identify patients at risk of mortality, with varying results. We hypothesized that the rapid
decline in lung function in IPF may be a consequence of an abnormal host response to pathogen-associated
molecular patterns (PAMPs), leading to aberrant activation in fibroblasts and fibrosis. Analysis of upper and lower
lobe surgical lung biopsies (SLBs) indicated that TLR9, a hypomethylated CpG DNA receptor, is prominently
expressed at the transcript and protein level, most notably in biopsies from rapidly progressive IPF patients.
Surprisingly, fibroblasts appeared to be a major cellular source of TLR9 expression in IPF biopsies from this group
of progressors. Further, CpG DNA promoted profibrotic cytokine and chemokine synthesis in isolated human IPF
fibroblasts, most markedly again in cells from patients with the rapidly progressive IPF phenotype, in a TLR9-
dependent manner. Finally, CpG DNA exacerbated fibrosis in an in vivo model initiated by the adoptive transfer of
primary fibroblasts derived from patients who exhibited rapidly progressing fibrosis. Together, these data suggested
that TLR9 activation via hypomethylated DNA might be an important mechanism in promoting fibrosis particularly
in patients prone to rapidly progressing IPF.
Introduction
IPF patients exhibit heterogeneous longitudinal behavior
that is best defined by using a combination of physiolo-
gical progression and clinical events. Identifying rapid
progression over the first year of follow-up is clinically
relevant given ongoing and planned therapeutic trials,
which are of approximately one-year duration. Identify-
ing which patients who are likely to experience rapid
progression over such a time frame would provide key
data in clinical decision-making and in the design of
future therapeutic trials, providing an opportunity for
personalized approaches to therapy. Unfortunately, base-
line clinical, physiological and radiological differences,
which identify these subgroups, have been difficult to
identify.
Identifying biologically relevant differences between
IPF patients that remain stable or show slow progression
compared to those who rapidly progress is an active area
of investigation but to date a detailed understanding of
the gene expression pattern in IPF patients segregated
into stable or rapidly progressive groups using standard
methodology is lacking. Our studies to date suggest this
is a promising avenue of investigation given that we have
identified a host response gene, TLR9, which is uniquely
upregulated in biopsies from rapidly progressing, but not
slowly progressing, IPF patients relative to normal biop-
sies [1]. More importantly, human fibroblasts derived
from lung biopsy material from rapidly progressing IPF
patients respond to TLR9 activation via CpG-ODN [1]. * Correspondence: hogaboam@med.umich.edu
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Physiology defines subgroups of IPF patients with
varying disease progression
A high degree of heterogeneity in longitudinal physiologi-
cal behavior is noted. In a group of 80 patients with IPF
we examined the predictive ability of serial change in FVC
over six or twelve months to predict subsequent survival
[2]. At six months of initial follow-up 32% while at 12
months 54% of IPF patients exhibited a greater than 10%
decrease in FVC. The predictive ability of a greater than
10% decrease in FVC at six months on subsequent mortal-
ity and the 12 month data were remarkably similar. In a
larger study of IPF patients (n = 197), we examined the
relationship of longitudinal change in FVC, DLCO or six
minute walk performance stratified by baseline six-minute
walk desaturation. An FVC decrease > 10% or a DLCO
decrease of at least 15% was shown to strongly predict
subsequent mortality or rapidly progressing IPF. Those
patients who did not show these changes in lung function
appeared to have a slower progressing IPF. Together,
these data support that longitudinal physiological behavior
can be used to segregate IPF patients into groups with dif-
fering long-term mortality, and physiological heterogeneity
is a strong predictor of longitudinal disease course.
Acute exacerbations contribute to mortality in IPF
patients
In the placebo arm of a large therapeutic trial, we
reported that 36 (21.4%) IPF patients died during 72
weeks of follow-up [3]. Death was considered by the pri-
mary investigators to be IPF-related in 89% of the cases.
In 47% of these IPF-related deaths, investigators charac-
terized disease progression as acute or abrupt suggesting
that an acute exacerbation of disease was the reason for
death. Figure 1 illustrates the longitudinal change in FVC
among the IPF patients who died abruptly (Panel A) and
those that died due to sub-acute deterioration (Panel B).
A decrease in FVC was not consistently noted in patients
who died acutely. These data highlight limitations of phy-
siological deterioration in predicting mortality and sug-
gested that additional endpoints are needed to define
longitudinal phenotype behavior in IPF. The occurrence
of acute exacerbations in IPF is an appropriate event-
based component of a marker for disease progression.
To clarify the definition of acute exacerbations for clin-
ical care and clinical trials a multinational, multi-investi-
gator committee was convened with support from the
NIH-sponsored Idiopathic Pulmonary Fibrosis Clinical
Research Network. Table 1 shows the criteria used for a
working diagnosis of an acute exacerbation. The totality
of these data suggests that a phenotypic definition of
rapid progression in IPF should include physiological
change (FVC and/or DLCO), acute exacerbation or
mortality (Table 2).
TLR9 transcript expression is markedly increased in upper
and lower lobe surgical lung biopsies from rapidly
progressive but not slow IPF
In order to test the hypothesis that rapid progression of
IPF might be a consequence of altered innate immune
sensing and responsiveness to pathogen associated mole-
cular patterns, we examined the relative levels of expres-
sion of TLR9 via quantitative PCR analysis in upper and
lower lobe open lung biopsies obtained from patients
with IPF compared with the histologically normal mar-
gins from resected lung tumors [1]. Normal tissues have
low transcript expression for TLR9. Quantitative PCR
analyses showed marked increases in the levels of expres-
sion of TLR9 in IPF SLBs relative to the levels of TLR9
expression detected in normal margins from resected
lung tumors. TLR9 transcript expression in SLBs from
rapidly progressive and slowly progressing IPF patients,
and it appeared that TLR9 transcript expression relative
to the normal biopsies was elevated in the rapidly pro-
gressive group versus slow IPF patients. Together, these
data suggested that increased TLR9 expression might
contribute to the rapidly progressive phenotype in IPF.
TLR9 is expressed in the interstitial areas of rapidly
progressive IPF SLBs
Molecular analysis through real time PCR showed that
TLR9 expression was higher in IPF SLBs than in normal
tissue; therefore to confirm these data and to localize the
cellular source of pulmonary TLR9 mRNA expression,
Figure 1 A. An inconsistent change in FVC is noted in IPF patients, who died acutely in the placebo arm of a large, randomized
therapeutic trial. B. Serial FVC change in IPF patients, who died subacutely in the placebo arm of a large, randomized therapeutic trial.
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tions from IPF and normal margin surgical resection spe-
cimens. TLR9 staining was detected in SLBs from IPF
patients. Of interest, TLR9 staining was localized not
only in morphologically distinct immune cells but also in
the alveolar epithelium (particularly in what appears
morphologically to be type II cells) and in the interstitial
areas of the IPF biopsies. TLR9 expression was present
only in morphologically distinct immune cells but was
not detected in interstitial areas of histologically normal
lung tissue. Thus, these data confirmed that TLR9 pro-
tein was prominently expressed in IPF biopsy material,
and provided evidence that the increase in TLR9 tran-
script expression in IPF was due to the expression of this
receptor by cell types not normally positive for TLR9.
TLR9-dependent, CpG ODN-induced cytokine and
chemokine synthesis was noted in rapidly progressive IPF
fibroblast cells but not slow IPF fibroblast cells
Based on the observation that TLR9 expression was
remarkably enhanced in the interstitial areas of biopsies
collected from patients affected by IPF, we have further
investigated the expression of TLR9 protein in cultured
IPF fibroblasts [4]. Using confocal microscopy, we
detected high levels of TLR9 in the cytoplasm of untreated
(i.e. media alone condition) fibroblasts from rapidly pro-
gressive IPF and the pattern of expression was homoge-
neous within the intracellular compartment. TLR9 was
detected in slow IPF fibroblasts but the levels of expres-
sion were much lower than those detected in the rapidly
progressive group. The TLR9 dependence of CpG ODN
effects on human IPF fibroblasts was assessed using chlor-
oquine. In these studies, the addition of CpG ODN to
fibroblast cultures drove the expression of PDGF-BB,
CXCL8, CXCL1, CCL5, CCL7, CCL11, and CCL2 in cul-
tures of rapidly progressive fibroblasts but not in fibro-
blasts from slow IPF. Also, the presence of chloroquine in
cultures of human fibroblasts reversed the CpG ODN
effect in rapidly progressive fibroblasts. Importantly, there
no evidence that this compound altered growth factor or
chemokine generation by IPF fibroblasts due to toxic or
non-specific effects when added alone. CCL2 in particular
is a potent profibrotic mediator in the lung [5-7].
Together, these data suggest that CpG ODN drives che-
mokine synthesis in fibroblasts from rapidly progressive
patients but not in fibroblasts from slow IPF patients. The
stimulatory effect of CpG ODN in the former group of
fibroblasts is TLR9-dependent.
CpG ODN exacerbates the fibrotic response in a SCID
model of IPF
To explore whether CpG ODN altered fibrosis in a model
of IPF in SCID mice developed in our laboratory [1,8], we
introduced CpG ODN by intranasal instillation into SCID
mice, which had been intravenously injected with either
normal fibroblast line or a rapidly progressive IPF human
fibroblast line 35 days previously. Normal human fibro-
blasts injected into SCID mice did not evoke a fibrotic
response in these mice as revealed by histological analysis
63 days later. The intranasal introduction of CpG ODN at
day 35 alone did not alter the lung remodeling response.
However, the introduction of IPF human fibroblasts alone
into SCID mice markedly remodeled the SCID mouse
lung 63 days later, and the fibrotic remodeling response in
SCID mice intravenously challenged with IPF fibroblasts
was dramatically enhanced with the CpG ODN treatment.
Thus, the presence of CpG ODN markedly exacerbated
t h ef i b r o t i cr e s p o n s ei n i t i a t e db yt h ei n t r o d u c t i o no f
human fibroblasts (a rapidly progressive line) into immu-
nodeficient mice and lends further support to our hypoth-
esis that altered responsiveness by fibroblasts to the
presence of hypomethylated DNA can accelerate the
course of fibrotic disease.
Discussion and conclusions
It is becoming increasingly clear that IPF is a designa-
t i o na p p l i e dt oag r o u po fp a t ients with heterogeneous
longitudinal courses. Nearly half of all deaths are due to
acute exacerbations superimposed on a chronic, more
slowly progressive disease course. Our findings suggest
that: 1) IPF patients exhibit variable longitudinal beha-
vior both physiologically and clinically; 2) serial pulmon-
ary function testing in combination with clinically
relevant events (acute exacerbations and/or mortality)
Table 1 Criteria suggested for defining an acute
exacerbation of IPF
Previous or concurrent diagnosis of IPF
Unexplained worsening or development of dyspnea within 30 days
HRCT with new bilateral ground-glass abnormality and/or consolidation
superimposed on a background reticular or honeycomb pattern
consistent with UIP
No evidence of pulmonary infection by endotracheal aspirate or
bronchoalveolar lavage
Exclusion of alternative causes, including the following:
Left heart failure
Pulmonary embolism
Identifiable cause of acute lung injury
Table 2 Methodology utilized to define slowly vs. rapidly
progressive IPF
Physiological (over first year of follow-up)
Consistent FVC decrease > 10%
Consistent DLCO decrease > 15%
Event based (over first year of follow-up)
All cause mortality
Acute exacerbation
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patients; 3) TLR9 is strongly upregulated in IPF biopsies
and expressed by IPF fibroblasts (most prominently in
rapidly progressive patients); and 4) CpG ODN drives
pro-fibrotic cytokines and chemokines in a TLR9-depen-
dent manner strongly supporting the connection
between host-environment interactions in pulmonary
fibrosis.
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